Newsroom

March 2020

• 
  Story Mar 26, 2020 Patient Perspectives

  Caring for someone with heart failure

  Caring for someone with heart failure can be both demanding and rewarding. Learn about the impact of being a carer and the support that carers need.

• Press release Mar 26, 2020

  Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

  Collaboration to address product development and scale up challenges posed by current pandemic Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an…
• Press release Mar 24, 2020

  Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

  Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones In addition to…
• Press release Mar 24, 2020

  AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2

  SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,…
• Press release Mar 20, 2020

  Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

  Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory…
• Ad hoc release Mar 19, 2020

  Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)

  Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at…
• Press release Mar 18, 2020

  Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

  Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk…
• Press release Mar 17, 2020

  Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities

  Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak  Novartis to join collaborative R…
• Featured News Mar 13, 2020

  Novartis coronavirus update (remote working, business travel restrictions)

• Featured News Mar 11, 2020

  Novartis provides update on use and safety of Beovu® in patients with wet AMD

• 
  Story Mar 11, 2020 Discovery

  The data42 program shows Novartis’ intent to go big on data and digital

  Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

• 
  Story Mar 11, 2020 Discovery

  Meet Achim, leading the data42 program

  The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.